Press Release

Mike Story Joins Scientific Advisory Board of Protein Discovery, Inc.

Knoxville, Tennessee, January 17, 2006—Protein Discovery, Inc., a privately held life sciences company, today announced that Mike Story, a key figure in the development and commercialization of mass spectrometry for biological sciences, has joined the company's scientific advisory board.

Mike Story co-designed the first commercial mass spectrometry system based on quadrupole technology and was a co-founder of Finnigan Corporation, which was acquired by Thermo Electron Corp (NYSE: TMO). Among his other accomplishments, Mr. Story initiated and successfully brought to market three major new mass spectrometry technologies originating from academic institutions.  He has detailed the requirements and specified the development of mass spectrometer-based instrumentation for analytical biochemists and molecular biologists, managed research and engineering groups, and founded, staffed, and managed successful distribution organizations worldwide.  He is the author of numerous technical articles in journals and trade publications, has written two chapters of books on quadrupole mass spectrometry, and holds seven patents in the area of mass spectrometry. Mr. Story graduated from the University of California at Berkeley with a BS degree in Chemistry and currently serves on the Board of Directors of Syagen Technology, Inc.

"Mike Story is one of the founders of the bioanalytical mass spec industry and has a long record of successful product development and commercialization in the industry. His experience is relevant to all key aspects of our business,"said Chuck Witkowski, chief executive officer of Protein Discovery. "In addition to helping us with science and technology issues, Mike is providing sound business advice, too, as we make our transition into commercialization. We're fortunate to have this advisory relationship with Mike and the benefit of his counsel."

"Protein Discovery is working on valuable technologies with marketable applications in research and clinical proteomics," said new SAB member Mike Story.  "The pharmaceutical and clinical industries are counting on the type of development breakthroughs I'm seeing at Protein Discovery to make mass spec a more practical and accessible method for routine, high-precision analysis."
Mike Story joins a distinguished roster of fellow scientists and inventors on Protein Discovery's scientific advisory board, including Richard Caprioli PhD, David Hachey PhD, Nathan Lewis PhD, Michael Sailor PhD, and Thomas Thundat PhD.

About Protein Discovery
Protein Discovery, Inc. is a privately held life sciences company developing solutions for molecular research, drug discovery and development, and medical diagnostics using high throughput mass spectrometry. The company’s imaging mass spectrometry (IMS) service allows pharmaceutical and clinical research customers to gain important insights into disease progression, treatment, and metabolic response. The company is also developing a powerful suite of sample preparation products specifically designed to meet the data quality and throughput demands of customers using mass spectrometry in the life sciences industry.  The ability to reproducibly identify and quantify suites of clinically significant biomarkers with spatial resolution will enhance patient health by improving the diagnosis, prognosis, and treatment of disease. For additional information, please visit www.proteindiscovery.com.

TOP